SE0400199D0 - HCV Protease inhbitors - Google Patents

HCV Protease inhbitors

Info

Publication number
SE0400199D0
SE0400199D0 SE0400199A SE0400199A SE0400199D0 SE 0400199 D0 SE0400199 D0 SE 0400199D0 SE 0400199 A SE0400199 A SE 0400199A SE 0400199 A SE0400199 A SE 0400199A SE 0400199 D0 SE0400199 D0 SE 0400199D0
Authority
SE
Sweden
Prior art keywords
compounds
protease inhibitors
hcv protease
cleavage site
linkage
Prior art date
Application number
SE0400199A
Other languages
English (en)
Swedish (sv)
Original Assignee
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir Ab filed Critical Medivir Ab
Priority to SE0400199A priority Critical patent/SE0400199D0/xx
Publication of SE0400199D0 publication Critical patent/SE0400199D0/xx
Priority to AU2005207816A priority patent/AU2005207816C1/en
Priority to AT05704764T priority patent/ATE461209T1/de
Priority to TW094102697A priority patent/TWI361195B/zh
Priority to EP05704764A priority patent/EP1713822B1/en
Priority to UAA200608624A priority patent/UA84050C2/ru
Priority to BRPI0506945-9A priority patent/BRPI0506945A/pt
Priority to DE602005019979T priority patent/DE602005019979D1/de
Priority to EP05704765A priority patent/EP1713823B1/en
Priority to NZ548739A priority patent/NZ548739A/en
Priority to PCT/SE2005/000096 priority patent/WO2005073216A2/en
Priority to RSP-2010/0036A priority patent/RS51243B/sr
Priority to TW094102721A priority patent/TWI367211B/zh
Priority to EA200601400A priority patent/EA014584B1/ru
Priority to US10/572,349 priority patent/US7671032B2/en
Priority to ARP050100340A priority patent/AR048401A1/es
Priority to AT05704765T priority patent/ATE448243T1/de
Priority to NZ548740A priority patent/NZ548740A/en
Priority to ES05704765T priority patent/ES2336009T3/es
Priority to MYPI20050347A priority patent/MY146349A/en
Priority to US10/572,418 priority patent/US7608590B2/en
Priority to CA2552317A priority patent/CA2552317C/en
Priority to EA200601399A priority patent/EA012410B1/ru
Priority to PL05704765T priority patent/PL1713823T3/pl
Priority to PL05704764T priority patent/PL1713822T3/pl
Priority to JP2006551001A priority patent/JP4902361B2/ja
Priority to PCT/SE2005/000097 priority patent/WO2005073195A2/en
Priority to ES05704764T priority patent/ES2342944T3/es
Priority to PT05704765T priority patent/PT1713823E/pt
Priority to SI200530899T priority patent/SI1713823T1/sl
Priority to CN2005800034238A priority patent/CN1914225B/zh
Priority to DE602005017582T priority patent/DE602005017582D1/de
Priority to DK05704764.9T priority patent/DK1713822T3/da
Priority to CA2552319A priority patent/CA2552319C/en
Priority to JP2006551000A priority patent/JP5248783B2/ja
Priority to KR1020127011467A priority patent/KR20120090077A/ko
Priority to MYPI20050349 priority patent/MY153011A/en
Priority to ARP050100341A priority patent/AR047793A1/es
Priority to UAA200608686A priority patent/UA84189C2/ru
Priority to BRPI0506948A priority patent/BRPI0506948B1/pt
Priority to KR1020067017480A priority patent/KR101159575B1/ko
Priority to CN200580003410.0A priority patent/CN1914224B/zh
Priority to AU2005207815A priority patent/AU2005207815B2/en
Priority to DK05704765.6T priority patent/DK1713823T3/da
Priority to IL176848A priority patent/IL176848A/en
Priority to IL176921A priority patent/IL176921A/en
Priority to EC2006006725A priority patent/ECSP066725A/es
Priority to EC2006006726A priority patent/ECSP066726A/es
Priority to CR8540A priority patent/CR8540A/es
Priority to CR8539A priority patent/CR8539A/es
Priority to NI200600168A priority patent/NI200600168A/es
Priority to KR1020067016960A priority patent/KR101217036B1/ko
Priority to NO20063850A priority patent/NO340695B1/no
Priority to NO20063851A priority patent/NO341392B1/no
Priority to ZA200607215A priority patent/ZA200607215B/en
Priority to ZA2006/07214A priority patent/ZA200607214B/en
Priority to HK07108629.5A priority patent/HK1100881A1/xx
Priority to HK07108691.8A priority patent/HK1104044A1/xx
Priority to US12/557,638 priority patent/US20100003216A1/en
Priority to US12/642,984 priority patent/US20100166706A1/en
Priority to HR20100048T priority patent/HRP20100048T1/hr
Priority to CY20101100134T priority patent/CY1109779T1/el
Priority to JP2010279178A priority patent/JP2011140488A/ja
Priority to JP2013234011A priority patent/JP5795619B2/ja
Priority to LU92595C priority patent/LU92595I2/xx
Priority to NL300703C priority patent/NL300703I2/nl
Priority to ARP160101214A priority patent/AR104445A2/es
Priority to US15/470,599 priority patent/US10172846B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
SE0400199A 2004-01-30 2004-01-30 HCV Protease inhbitors SE0400199D0 (sv)

Priority Applications (68)

Application Number Priority Date Filing Date Title
SE0400199A SE0400199D0 (sv) 2004-01-30 2004-01-30 HCV Protease inhbitors
AU2005207816A AU2005207816C1 (en) 2004-01-30 2005-01-28 HCV NS-3 serine protease inhibitors
AT05704764T ATE461209T1 (de) 2004-01-30 2005-01-28 Hcv ns-3 serine protease inhibitoren
TW094102697A TWI361195B (en) 2004-01-30 2005-01-28 Hcv ns-3 serine protease inhibitors
EP05704764A EP1713822B1 (en) 2004-01-30 2005-01-28 Hcv ns-3 serine protease inhibitors
UAA200608624A UA84050C2 (xx) 2004-01-30 2005-01-28 Інгібітори серин-протеази ns-3 hcv$ингибиторы серин-протеазы ns-3 hcv
BRPI0506945-9A BRPI0506945A (pt) 2004-01-30 2005-01-28 inibidores de serina protease ns-3 de hcv
DE602005019979T DE602005019979D1 (en) 2004-01-30 2005-01-28 Hcv ns-3 serine protease inhibitoren
EP05704765A EP1713823B1 (en) 2004-01-30 2005-01-28 Hcv ns-3 serine protease inhibitors
NZ548739A NZ548739A (en) 2004-01-30 2005-01-28 HCV NS-3 Serine protease inhibitors
PCT/SE2005/000096 WO2005073216A2 (en) 2004-01-30 2005-01-28 Hcv ns-3 serine protease inhibitors
RSP-2010/0036A RS51243B (sr) 2004-01-30 2005-01-28 Inhibitori ns-3 serina hcv proteaze
TW094102721A TWI367211B (en) 2004-01-30 2005-01-28 Hcv ns-3 serine protease inhibitors
EA200601400A EA014584B1 (ru) 2004-01-30 2005-01-28 Ингибиторы ns-3 сериновой протеазы hcv
US10/572,349 US7671032B2 (en) 2004-01-30 2005-01-28 HCV NS-3 serine protease inhibitors
ARP050100340A AR048401A1 (es) 2004-01-30 2005-01-28 Inhibidores de la serina-proteasa ns3 del vhc
AT05704765T ATE448243T1 (de) 2004-01-30 2005-01-28 Hcv ns-3 serine protease inhibitoren
NZ548740A NZ548740A (en) 2004-01-30 2005-01-28 HCV NS-3 Serine protease inhibitors
ES05704765T ES2336009T3 (es) 2004-01-30 2005-01-28 Inhibidores de la ns-3 serina proteasa del vhc.
MYPI20050347A MY146349A (en) 2004-01-30 2005-01-28 Hcv ns-3 serine protease inhibitors
US10/572,418 US7608590B2 (en) 2004-01-30 2005-01-28 HCV NS-3 serine protease inhibitors
CA2552317A CA2552317C (en) 2004-01-30 2005-01-28 Hcv ns-3 serine protease inhibitors
EA200601399A EA012410B1 (ru) 2004-01-30 2005-01-28 Ингибиторы серин-протеазы ns-3 hcv
PL05704765T PL1713823T3 (pl) 2004-01-30 2005-01-28 Inhibitory proteazy serynowej NS-3 HCV
PL05704764T PL1713822T3 (pl) 2004-01-30 2005-01-28 Inhibitory proteazy serynowej HCV NS-3
JP2006551001A JP4902361B2 (ja) 2004-01-30 2005-01-28 Ｈｃｖｎｓ−３セリンプロテアーゼインヒビター
PCT/SE2005/000097 WO2005073195A2 (en) 2004-01-30 2005-01-28 Hcv ns-3 serine protease inhibitors
ES05704764T ES2342944T3 (es) 2004-01-30 2005-01-28 Inhibidores de ns-3 serina proteasa de vhc.
PT05704765T PT1713823E (pt) 2004-01-30 2005-01-28 Inibidores da protease ns-3 da serina do hcv
SI200530899T SI1713823T1 (sl) 2004-01-30 2005-01-28 Inhibitorji HCV NS-3 serin proteaze
CN2005800034238A CN1914225B (zh) 2004-01-30 2005-01-28 Hcv ns-3丝氨酸蛋白酶抑制剂
DE602005017582T DE602005017582D1 (en) 2004-01-30 2005-01-28 Hcv ns-3 serine protease inhibitoren
DK05704764.9T DK1713822T3 (da) 2004-01-30 2005-01-28 HCV NS-3 serine protease inhibitorer
CA2552319A CA2552319C (en) 2004-01-30 2005-01-28 Hcv ns-3 serine protease inhibitors
JP2006551000A JP5248783B2 (ja) 2004-01-30 2005-01-28 Ｈｃｖｎｓ−３セリンプロテアーゼインヒビター
KR1020127011467A KR20120090077A (ko) 2004-01-30 2005-01-28 Ｈｃｖ ｎｓ?３ 세린 프로테아제 저해제
MYPI20050349 MY153011A (en) 2004-01-30 2005-01-28 Hcv ns-3 serine protease inhibitors
ARP050100341A AR047793A1 (es) 2004-01-30 2005-01-28 Inhibidores de la serina proteasa ns-3 del vhc
UAA200608686A UA84189C2 (xx) 2004-01-30 2005-01-28 Інгібітори ns-3 серинової протеази hcv$ингибиторы ns-3 сериновой протеазы hcv
BRPI0506948A BRPI0506948B1 (pt) 2004-01-30 2005-01-28 inibidores de serina protease ns-3 de hcv
KR1020067017480A KR101159575B1 (ko) 2004-01-30 2005-01-28 Ｈｃｖ ｎｓ―３ 세린 프로테아제 저해제
CN200580003410.0A CN1914224B (zh) 2004-01-30 2005-01-28 Hcv ns-3丝氨酸蛋白酶抑制剂
AU2005207815A AU2005207815B2 (en) 2004-01-30 2005-01-28 HCV NS-3 serine protease inhibitors
DK05704765.6T DK1713823T3 (da) 2004-01-30 2005-01-28 HCV NS-3 serinproteaseinhibitorer
IL176848A IL176848A (en) 2004-01-30 2006-07-13 Compounds of 3– hcv ns Serine Protease, Pharmaceutical Preparations Containing and Using Them
IL176921A IL176921A (en) 2004-01-30 2006-07-18 Hcv ns-3 serine protease inhibitors, pharmaceutical compositions comprising them and uses thereof in the manufacture of a medicament for the prophylaxis or treatment of flavivirus infections such as hcv
EC2006006725A ECSP066725A (es) 2004-01-30 2006-07-24 Inhibidores de serina proteasa ns-3 del vhc
EC2006006726A ECSP066726A (es) 2004-01-30 2006-07-24 Inhibidores de serina proteasa ns-3 del vhc
CR8540A CR8540A (es) 2004-01-30 2006-07-28 Inhibidores de serina proteasa ns-3 del vhc
CR8539A CR8539A (es) 2004-01-30 2006-07-28 Inhibidores de serina proteasa ns-3 del vhc
NI200600168A NI200600168A (es) 2004-01-30 2006-07-28 Inhibidores de serina proteasa ns-3 del vhc
KR1020067016960A KR101217036B1 (ko) 2004-01-30 2006-08-23 Ｈｃｖ ｎｓ－３ 세린 프로테아제 저해제
NO20063850A NO340695B1 (no) 2004-01-30 2006-08-29 HCV NS-3 Serinproteasehemmere
NO20063851A NO341392B1 (no) 2004-01-30 2006-08-29 HCV NS3-serinproteasehemmere
ZA200607215A ZA200607215B (en) 2004-01-30 2006-08-29 HCV NS-3 serine protease inhibitors
ZA2006/07214A ZA200607214B (en) 2004-01-30 2006-08-29 Hcv ns-3 serine protease inhibitors
HK07108629.5A HK1100881A1 (en) 2004-01-30 2007-08-08 Hcv ns-3 serine protease inhibitors hcv ns-3
HK07108691.8A HK1104044A1 (en) 2004-01-30 2007-08-10 Hcv ns-3 serine protease inhibitors hcv ns-3
US12/557,638 US20100003216A1 (en) 2004-01-30 2009-09-11 HCV NS-3 Serine Protease Inhibitors
US12/642,984 US20100166706A1 (en) 2004-01-30 2009-12-21 Hcv ns-3 serine protease inhibitors
HR20100048T HRP20100048T1 (hr) 2004-01-30 2010-01-27 Inhibitori hcv ns-3 serin proteaze
CY20101100134T CY1109779T1 (el) 2004-01-30 2010-02-10 Αναστολεις της hcv ns-3 πρωτεασης σερινης
JP2010279178A JP2011140488A (ja) 2004-01-30 2010-12-15 Ｈｃｖｎｓ−３セリンプロテアーゼインヒビター
JP2013234011A JP5795619B2 (ja) 2004-01-30 2013-11-12 Ｈｃｖｎｓ−３セリンプロテアーゼインヒビター
LU92595C LU92595I2 (fr) 2004-01-30 2014-11-11 Siméprévir, ou l'un de ses sels pharmaceutiquementacceptables, incluant siméprévir sodium
NL300703C NL300703I2 (nl) 2004-01-30 2014-11-12 Simeprevir, of een farmaceutisch aanvaardbaar zout daarvan, waaronder simeprevirnatrium.
ARP160101214A AR104445A2 (es) 2004-01-30 2016-04-28 Compuestos inhibidores de la serina proteasa ns3 del vhc y composición farmacéutica
US15/470,599 US10172846B2 (en) 2004-01-30 2017-03-27 HCV NS-3 serine protease inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0400199A SE0400199D0 (sv) 2004-01-30 2004-01-30 HCV Protease inhbitors

Publications (1)

Publication Number Publication Date
SE0400199D0 true SE0400199D0 (sv) 2004-01-30

Family

ID=31713267

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0400199A SE0400199D0 (sv) 2004-01-30 2004-01-30 HCV Protease inhbitors

Country Status (5)

Country Link
CN (2) CN1914224B (xx)
AR (1) AR104445A2 (xx)
NO (1) NO340695B1 (xx)
SE (1) SE0400199D0 (xx)
ZA (1) ZA200607215B (xx)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20070211A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
CN108101811A (zh) * 2016-11-25 2018-06-01 斯福瑞（南通）制药有限公司 生产n-叔丁氧羰基-2-氨基-3,3-二甲基丁酸的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1283906C (en) * 1983-05-09 1991-05-07 Makoto Sunagawa .beta.-LACTAM COMPOUNDS AND PRODUCTION THEREOF
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors

Also Published As

Publication number Publication date
NO340695B1 (no) 2017-06-06
ZA200607215B (en) 2008-05-28
CN1914224A (zh) 2007-02-14
CN1914225B (zh) 2012-09-26
NO20063850L (no) 2006-08-29
AR104445A2 (es) 2017-07-19
CN1914224B (zh) 2014-01-29
CN1914225A (zh) 2007-02-14

Similar Documents

Publication Publication Date Title
MY153011A (en) Hcv ns-3 serine protease inhibitors
ATE486889T1 (de) Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
ATE474827T1 (de) Hcv-replikationshemmer
NO20075616L (no) Tripeptider som hepatitt C virus inhibitorer
UY28525A1 (es) Péptidos macrociclicos activos contra en virus de la hepatitis c
AR030591A1 (es) Inhibidores de proteasa peptidomimetica
ATE492558T1 (de) Makrocyclische peptide als hepatitis-c-virus- hemmer
NO20091846L (no) Makrocykliske peptider som hepatitt C virus- inhibitorer
WO2007089618A3 (en) Hepatitis c serine protease inhibitors and uses therefor
TW200615275A (en) Hepatitis C inhibitor dipeptide analogs
ECSP045191A (es) "nuevos péptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c"
CL2012000919A1 (es) Composicion que comprende un compuesto derivado de metoxicarbonil-amino-metilbutanoil-pirrolidinil-imidazol de formula i, inhibidor especifico de ns5a de hcv, y un compuesto derivado de oxo-pirrolidin-quinoleina de formula ii, inhibidor de proteasa ns3 de hcv; y uso en el tratamiento de la hepatitis c.
ATE512971T1 (de) Peptidanaloga als hepatitis c-hemmer
UA83046C2 (ru) Соединения как ингибиторы вируса гепатита с, фармацевтическая композиция на их основе
DE60309433D1 (de) Pharmazeutische zusammensetzungen für protease-hemmer für hepatitis-c-virus
UY28722A1 (es) Peptidos macrociclicos activos contra el virus del a hepatitis c
MX2012006877A (es) Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado.
WO2007016476A3 (en) Hepatitis c serine protease inhibitors and uses therefor
CL2009000305A1 (es) Compuestos derivados de 2-aril-sustituido-1-benzofurano-3-carboxamida, inhibidores de la polimerasa ns5b; composicion farmaceutica; y su uso en el tratamiento de una enfermedad causada por el virus de la hepatitis c (hcv).
TW200728317A (en) Macrocylic inhibitors of hepatitis C virus
GEP20094751B (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
AR043929A1 (es) Fases cristalinas de un inhibidor del hcv
WO2007092645A3 (en) Novel hcv inhibitor combinations and methods
DK1558730T3 (da) Inhibitorresistent HCV-NS3-protease
WO2010034105A8 (en) Hepatitis c inhibitor compounds